HISLA and cancer: This study demonstrates that RNA-interference-mediated silencing of HISLA may be a potentially powerful means to inhibit glycolytic processes in cancer cells, and they demonstrate that targeting TAMs-specific lncRNAs has great potential in cancer therapy.